What is William Blair's Estimate for AUTL FY2029 Earnings?

Key Points

• William Blair analyst M. Phipps has projected that Autolus Therapeutics will report earnings of $0.54 per share for FY2029, contrasting sharply with the consensus estimate of ($0.94) per share for the current year.
• In its most recent earnings report, Autolus Therapeutics exceeded expectations by posting ($0.18) earnings per share, surpassing the consensus estimate of ($0.24).
• Autolus Therapeutics has received positive ratings from multiple brokerages, with a consensus buy rating and a projected price target of $9.12 according to MarketBeat data.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) - Equities researchers at William Blair issued their FY2029 EPS estimates for shares of Autolus Therapeutics in a research note issued on Tuesday, August 12th. William Blair analyst M. Phipps forecasts that the company will post earnings of $0.54 per share for the year. The consensus estimate for Autolus Therapeutics' current full-year earnings is ($0.94) per share.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.06. The company had revenue of $13.50 million during the quarter, compared to analyst estimates of $12.92 million.

A number of other brokerages have also recently weighed in on AUTL. Needham & Company LLC reiterated a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a research note on Monday, July 21st. Wells Fargo & Company decreased their price target on shares of Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating for the company in a research note on Wednesday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $9.12.

Autolus Therapeutics Price Performance

Shares of Autolus Therapeutics stock traded up $0.11 during trading hours on Thursday, hitting $1.95. The company had a trading volume of 451,781 shares, compared to its average volume of 1,788,141. The company's 50-day moving average is $2.34 and its two-hundred day moving average is $1.90. Autolus Therapeutics has a twelve month low of $1.11 and a twelve month high of $5.00. The company has a market cap of $517.64 million, a P/E ratio of -2.34 and a beta of 1.90.

Hedge Funds Weigh In On Autolus Therapeutics

Large investors have recently made changes to their positions in the stock. Jane Street Group LLC purchased a new position in shares of Autolus Therapeutics in the 4th quarter valued at about $26,000. Barclays PLC increased its holdings in shares of Autolus Therapeutics by 1,094.3% in the 4th quarter. Barclays PLC now owns 11,859 shares of the company's stock valued at $28,000 after purchasing an additional 10,866 shares in the last quarter. R Squared Ltd purchased a new position in Autolus Therapeutics during the 2nd quarter valued at about $50,000. Delaney Dennis R purchased a new position in Autolus Therapeutics during the 2nd quarter valued at about $55,000. Finally, Virtus ETF Advisers LLC increased its holdings in Autolus Therapeutics by 29.9% during the 4th quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company's stock valued at $62,000 after acquiring an additional 6,081 shares in the last quarter. Hedge funds and other institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.